Menu Search
Equities

Eli Lilly and Co

LLY:DEU

Eli Lilly and Co

Actions
  • Price (EUR)108.54
  • Today's Change-0.34 / -0.31%
  • Shares traded834.00
  • 1 Year change8.44%
  • Beta0.1638
Data delayed at least 15 minutes, as of Dec 10 2019 18:17 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

  • Revenue in USD (TTM)22.64bn
  • Net income in USD4.44bn
  • Incorporated1901
  • Employees38.68k
  • Location
    Eli Lilly and CoLilly Corporate CtrDrop Code 1094, Lilly Corporate CtrINDIANAPOLIS 46285-0001United StatesUSA
  • Phone+1 (317) 276-2000
  • Fax+1 (317) 276-3492
  • Websitehttps://www.lilly.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		LLY:NYQ since
announced		Transaction
value
Loxo Oncology IncDeal completed07 Jan 201907 Jan 2019Deal completed4.93%7.99bn
Data delayed at least 15 minutes, as of Dec 10 2019 19:33 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.